Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
MYNZ
MYNZ
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MYNZ News
Mainz Biomed Launches eAArly DETECT 2 Clinical Study Covering 2,000 Patients
Jan 05 2026
Globenewswire
Mainz Biomed Integrates ColoAlert® Test into DoctorBox Platform in Germany
Dec 02 2025
Globenewswire
Mainz Biomed Partners with DoctorBox to Launch ColoAlert Test in Germany
Dec 02 2025
Newsfilter
Mainz Biomed and OncoVanguard8 Partner to Introduce ColoAlert in South America
Nov 18 2025
Newsfilter
Mainz Biomed to Showcase ColoAlert, Its Leading Product, at MEDICA 2025
Nov 12 2025
NASDAQ.COM
Mainz Biomed to Participate in the 38th Annual GARPS Meeting in Rhineland-Palatinate
Nov 10 2025
Newsfilter
Mainz Biomed to Showcase Innovations in Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
Sep 30 2025
Newsfilter
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
Aug 13 2025
Newsfilter
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
Aug 04 2025
Newsfilter
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
Jul 15 2025
Newsfilter
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
Jun 25 2025
Newsfilter
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Jun 10 2025
Newsfilter
Mainz Biomed Initiates Feasibility Study Of PancAlert Blood Test For Pancreatic Cancer Detection
Jun 10 2025
NASDAQ.COM
Will AI Empower the PR Industry or Create Endless Seas of Spam?
May 21 2025
WSJ
Mainz Biomed prices $4M securities offering
May 20 2025
SeekingAlpha
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants
May 20 2025
Newsfilter
Show More News